ArticleArchives of orthopaedic and trauma surgery2026
Only a partial shield: local vancomycin postpones but does not prevent hip and knee prosthetic infections.
Article in Archives of orthopaedic and trauma surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeriprosthetic joint infection (PJI) represents a severe complication following total hip arthroplasty (THA) and total knee arthroplasty (TKA). The intraarticular application of vancomycin powder is increasingly integrated into perioperative standards as an innovative strategy for PJI prevention. Yet the efficacy of this method remains a topic of debate. The aim of this retrospective cohort study was to evaluate whether topical vancomycin application reduces the incidence of PJI after primary total joint arthroplasty (TJA) and whether it is associated with an increased risk of wound complications. MATERIALS AND
methodsIn this retrospective monocentric cohort study, all primary THA and TKA procedures performed between January 1, 2022, and December 31, 2023, were analysed. From January 1, 2023, intraarticular vancomycin powder was implemented as part of the standard perioperative protocol for PJI prevention. The PJI rates, postoperative surgery-related complications, and time to infection were compared between the vancomycin and control groups.
resultsA total of 1,499 patients were included in the study. Patients were divided into two groups: a vancomycin group (VG, n = 818) and a control group (CG, n = 681). No statistically significant group differences were observed for wound healing disorders (p = 0.775) or PJI rates (1.0% VG vs. 0.9% CG, p = 0.846). However, there was a statistically significant delay in the onset of infection in the VG compared to the CG (41.5 vs. 16.5 days, p = 0.006).
conclusionIntraarticular application of vancomycin powder was not associated with a reduction in overall PJI rates after primary TJA but appeared to be associated with a longer time to infection. These findings may suggest that local vancomycin application delays the clinical manifestation of infection rather than preventing it, potentially complicating the diagnosis of PJI and limiting less invasive treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.